Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 7 pages · Chinese
CanSino Biologics, Inc. on 6ix
Earlier from CanSino Biologics
- Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
- Announcement on Renewing Engagement of Accounting Firm
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine
- Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties
Later from CanSino Biologics
- Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on the Obtainment of Drug Registration Certificate for 13-valent Pneumococcal Polysaccharide Vaccine (CRM197/Tetanus Toxoid)
- -- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)
- -- Announcement on Using Temporarily Idle Raised Funds for Cash Management
Follow CanSino Biologics into a list and get an email when it puts out news.
Follow CanSino Biologics